4694-91-1

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Nitro benzoxazolinone is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be converted into various functional groups, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 6-Nitro benzoxazolinone is utilized as a precursor in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Dye Manufacturing:
6-Nitro benzoxazolinone is employed as a starting material in the manufacturing of dyes, particularly fluorescent dyes, due to its potential to be transformed into different chromophores that exhibit specific light-absorbing and emitting properties.
Used in Organic Synthesis:
As a versatile intermediate, 6-Nitro benzoxazolinone is used in organic synthesis for the preparation of a wide range of chemical compounds, taking advantage of its reactivity and the possibility of functional group transformations to achieve desired molecular structures.

InChI:InChI=1/C7H4N2O4/c10-7-8-5-2-1-4(9(11)12)3-6(5)13-7/h1-3H,(H,8,10)

Upstream product

• 59-49-4 2-Benzoxazolinone 
• 98550-12-0 2-hydroxy-4-nitro-benzohydroxamic acid 
• 75-44-5 phosgene 
• 121-88-0 5-Nitro-2-aminophenol 
• 131761-69-8 2,4-dihydroxy-7-nitro-2H-1,4-benzoxazin-3-one 
• 530-62-1 1,1'-carbonyldiimidazole 
• 14541-93-6 6-nitrobenzo[d]oxazole-2(3H)-thione 
• 554-84-7 meta-nitrophenol 
• 14235-05-3 3-nitrophenyl chloroformate 
• 95-55-6 2-amino-phenol 
• 43112-57-8 N,O-bistrimethylsilyl-2-amino-5-nitrophenol 
• 88522-68-3 4-nitro-2-hydroxyphenylurea 
• 38880-75-0 (2-hydroxy-4-nitro-phenyl)-carbamic acid ethyl ester 

Downstream Products

• 99419-94-0 3-benzenesulfonyl-6-nitro-3H-benzoxazol-2-one 
• 106590-31-2 6-nitro-3-(toluene-4-sulfonyl)-3H-benzoxazol-2-one 
• 33124-31-1 5,6-dinitro-3-benzoxazolin-2-one 
• 38191-31-0 4-(2-hydroxy-4-nitro-phenyl)-semicarbazide 
• 22876-17-1 6-amino-1,3-benzoxazol-2-(3H)-one 
• 19231-18-6 6-nitro-3-(tri-O-benzoyl-β-D-ribopyranosyl)-3H-benzooxazol-2-one 
• 108176-84-7 6-nitro-3-<4-(N-morpholinomethyl)phenylaminomethyl>benzoxazolin-2-one 
• 3316-09-4 1,2-dihydroxy-4-nitrobenzene 
• 7664-41-7 ammonia 
• 120007-54-7 5,6-Dinitro-3-(2-oxo-2-phenyl-ethyl)-3H-benzooxazol-2-one 
• 99584-10-8 6-amino-3-methyl-1,3-benzoxazol-2(3H)-one 
• 81110-79-4 (2-oxo-2,3-dihydro-benzoxazol-6-yl)-urea 
• 16292-99-2 2-(methylamino)-5-nitrophenol 
• 102024-56-6 N'-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-N,N-diphenyl-urea 

Relevant academic research and scientific papers

Versatile Cp*Co(III)(LX) Catalyst System for Selective Intramolecular C-H Amidation Reactions

Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed regioselectivity was rationalized by the conformational analysis and DFT calculations of the transition states. The superior performance of the newly developed cobalt catalyst system could be broadly applied to both C(sp2)-H and C(sp3)-H carbamation reactions under mild conditions.

POLYAMINO BIARYL COMPOUNDS AND THEIR USE

The present invention is directed to novel compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, and their use.

AGENT FOR OXIDATIVE DYEING OF HAIR CONTAINING ANISOLE DERIVATIVES

The present disclosure relates to agents for the oxidative coloring of keratinic fibers, which are characterized in hat they contain derivatives of anisole as novel developer molecules.

A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors

Dysregulation of the Amyloid Precursor Protein (APP) processing leading to toxic species of amyloid β peptides (Aβ) is central to Alzheimer's disease (AD) etiology. Aβ peptides are produced by sequential cleavage of APP by β-secretase (BACE-1) and γ-secretase. Lysosomotropic agent, chloroquine (CQ), has been reported to inhibit Aβ peptide production. However, this effect is accompanied by an inhibition of lysosome-mediated degradation pathways. Following on from the promising activity of two series of APP metabolism modulators derived from CQ, we sought to develop new series of compounds that would retain the inhibitory effects on Aβ production without altering lysosome functions. Herein, we applied a ligand-based pharmacophore modeling approach coupled with de novo design that led to the discovery of a series of biaryl compounds. Structure-activity relationship studies revealed that minor modifications like replacing a piperidine moiety of compound 30 by a cyclohexyl (compound 31) allowed for the identification of compounds with the desired profile. Further studies have demonstrated that compounds 30 and 31 act through an indirect mechanism to inhibit β-secretase activity. This work shows that it is possible to dissociate the inhibitory effect on Aβ peptide secretion of CQ-derived compounds from the lysosome-mediated degradation effect, providing a new profile of indirect β-secretase inhibitors.

Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands

The 4-benzylpiperidine moiety is a central structural element of potent N-methyl-d-aspartate (NMDA) receptor antagonists containing the GluN2B subunit. To obtain novel GluN2B ligands suitable for positron emission tomography, the benzylpiperidine moiety was replaced with fluorinated ω-phenylalkylamino groups. For this purpose three primary propyl- and butylamines 7 a–c and one butyraldehyde 7 d bearing a fluorine atom and an ω-phenyl moiety were prepared in 3- to 7-step syntheses. Compounds 7 a–d were attached to various scaffolds of potent GluN2B antagonists (scaffold hopping) instead of the original 4-benzylpiperidine moiety. Although benzoxazol-2-ones and indoles with a benzylpiperidine moiety show high GluN2B affinity, the corresponding fluorophenylalkylamine derivatives did not result in high Glu2B affinity. Moderate GluN2B affinity was observed for a 3-(fluoroalkyl)-substituted tetrahydro-1H-3-benzazepine (Ki=239 nm). However, high GluN2B affinity was obtained for the tetrahydro-5H-benzo[7]annulen-7-amines 12 a–c (Ki=17–30 nm). Docking studies resulted in the same binding pose for 12 a as for the lead compound Ro 25-6981. It can be concluded that some GluN2B ligands (benzoxazolones, indoles) do not tolerate replacement of the 4-benzylpiperidine moiety with flexible fluorinated phenylalkyl side chains, but other scaffolds such as tetrahydro-3-benzazepines and -benzo[7]annulenes retain interaction with NMDA receptors containing the GluN2B subunit.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Method for producing 5-nitro-2aminophenol

The invention relates to a method for producing 5-nitro-2aminophenol.Ortho-aminophenol, urea and sulfuric acid have a cyclization reaction in a three-mouth round-bottom flask to obtain a benzoxazolone compound, then the obtained benzoxazolone compound, acidic imidazolium ionic liquid and nitric acid are placed in the round-bottom flask for a nitration reaction to obtain 6-nitryl benzoxazolone, and finally 5-nitro-2aminophenol is obtained through hydrolysis of sodium hydroxide.According to the method, in the step that the obtained benzoxazolone compound, acidic imidazolium liquid and nitric acid are placed in the round-bottom flask for the nitration reaction to obtain 6-nitryl benzoxazolone, the acidic imidazolium ionic liquid takes the place of 1,2-dichloroethane solvent in the prior art, the safety coefficient is remarkably improved, cost is low, and environmental friendliness is achieved.

Comparative study of conventional and microwave-assisted synthesis of novel 6-(arylideneamino)benzo[d]oxazol-2(3H)-ones with potential antibacterial activity

(Formula presented) The synthesis and characterization of novel class of Schiff bases derivatives 6-(Benzylideneamino)benzo[d]oxazol-2(3H)-ones (5a-d and 6a-d), derived from the condensation reactions of different aromatic aldehydes with 6-amino-2(3H)-benzoxazolone and 3-methyl-6-amino-2(3H)-benzoxazolone, using conventional and microwave irradiation methods was described. The structure of all newly synthesized compounds has been proven by using various spectral methods such as IR, 1H-NMR and 13C-NMR. The results confirmed that benzoxazolinonic amino group reacted with aromatic aldehydes to form the desired Schiff bases.

Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies

Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis. The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity. AC inhibitors may be useful in the treatment of pathological conditions, such as cancer, in which ceramide levels are abnormally reduced. Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice. We examined a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain. Several modifications enhanced potency and stability, and one key compound with a balanced activity-stability profile (14) was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration. The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compounds as pharmacological tools and their potential development as drug leads.

Experimental and theoretical investigation of the intramolecular cyclisation of N-(benzoxazolinon-6-Yl) Maleimide derivatives

A new N-H and N-CH3 2(3H)-benzoxazolones substituted at the C6 position in the aromatic ring by imide group (maleimides) has been synthesized in good yields. The regioselectivity of the cyclisation step has been investigated through DFT calculations at the B3LYP/6-31G (d,p) level of theory. The obtained results indicate that the maleimide is favored both kinetically and thermodynamically as observed experimentally.